Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Aug 30, 2013 11:08pm

792 Views

Post# 21711166

RE:RE:RE:RE:RE:RE:RE:RE:A few tidbits

yup. u got it wittmann. It's always up to us to DD, but sometimes you come across a gem here and there :)

DND was a no brainer. FCF positive, decent cash on the balance relative to its market cap, low trading valuation. I also LOVE companies where insiders own serious stock.

The deal closer for me was the fact that the guy behind DND spun it out of CML Healthcare before it got taken out by LIFELABS (OMERS) for $1 bln.lol This guy will do it again.

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row